WP2: The impact of obesity on disease
Understanding how obesity contributes to disease development through biological and clinical mechanisms.
Work Package 2 focuses on how obesity influences the development and progression of specific diseases. The aim is to investigate both the prevalence of obesity-related conditions and the biological mechanisms linking obesity to disease.
By combining clinical data, experimental approaches, and advanced biomarker analyses, WP2 seeks to improve understanding of disease pathways and support earlier detection and better risk stratification.
Sub-work packages
WP2a - Obesity and breath
(Lead: Ole Hilberg)
WP2a investigates obesity-related breathing disorders, including hypoventilation and obstructive sleep apnea, and how these are influenced by factors such as body composition and metabolic status.
The work includes studies of disease prevalence, longitudinal follow-up, and evaluation of how weight loss interventions and bariatric surgery affect pulmonary function and disease severity.
WP2b - Obesity and thromboinflammation
(Lead: Else-Marie Bladbjerg)
WP2b explores the interaction between coagulation and inflammation (thromboinflammation) and how this contributes to obesity-related disease.
The aim is to identify novel biomarkers of thromboinflammation and improve understanding of disease mechanisms, including why some individuals with obesity develop complications while others do not.
WP2c - Cardiometabolic protein profile
(Lead: Martin Overgaard)
WP2c investigates the role of cardiometabolic proteins as biomarkers for obesity-related diseases.
Using advanced proteomic analyses, this work focuses on identifying protein signatures associated with metabolic, cardiovascular, and liver-related conditions to enable earlier risk stratification.
WP2d - Obesity and liver disease
(Lead: Mette Munk Lauridsen)
WP2d studies the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and related liver fibrosis.
The work includes identifying early biomarkers, mapping disease trajectories, and evaluating the effects of weight loss interventions and treatments on liver outcomes.